Co-Labeling Sample Clauses
The CO-LABELING clause establishes the terms under which two or more parties may jointly brand, label, or market a product or service. Typically, this clause outlines how each party's trademarks, logos, or brand identifiers will be displayed, the approval process for co-labeled materials, and any restrictions on use. Its core practical function is to ensure that both parties' branding interests are protected and clearly defined, preventing misuse or misrepresentation while enabling collaborative marketing efforts.
Co-Labeling. To the extent not prohibited by law or regulation, Drug Products (including labels, packaging and inserts, whether in written or electronic form) and all promotional and educational materials (in any form) for the same, sold in North America, the countries of the European Union and Japan will bear both Avalon’s and Vertex’s company names and logos with equal prominence (including equal sized type face), or if equal prominence is prohibited by law, with the most comparable prominence as may otherwise be permitted by law. To the extent not prohibited by law or regulation, Drug Products (including labels, packaging and inserts) and all promotional materials for the same, sold in the rest of the world will include Vertex’s company name (in the English alphabet) and logo with the designation: “under license from.” Any trademark for a Drug Product will be selected by, and will be the property of, Avalon.
Co-Labeling. The labels, packaging and inserts for the Drug Product packaged for sale in the Territory, and any promotional materials therefor, will bear the company names and logos of both MITSUBISHI and VERTEX with such relative prominence and in such language as are permitted by the applicable laws, rules, regulations and custom of such country, with the preference that wherever possible such names and logos shall be of equal prominence and VERTEX’s name shall be written in the English language. MITSUBISHI will permit VERTEX to review all material regulatory filings in the Territory that relate to product labeling, and all proposed labels, packaging, package inserts and promotional materials required under the foregoing provisions to bear VERTEX’s name and logo, prior to the filing of any such material with any Regulatory Authority.
Co-Labeling. To the extent not prohibited by law or regulation and subject to any required Regulatory Approval, Drug Products (including labels, packaging and inserts) and all promotional materials for the same, sold in North America, the countries of the European Union and Japan will bear both NOVARTIS' and VERTEX's company names and logos with equal prominence (including equal sized type face), or if equal prominence is prohibited by law, with such prominence as may otherwise be permitted by law. To the extent not prohibited by law or regulation and subject to any required Regulatory Approval, Drug Products (including labels, packaging and inserts) and all promotional materials for the same, sold in the rest of the world will include VERTEX's company name (in the English alphabet) and logo with the designation: "under license from"; provided, however, that this provision shall no longer apply in case of a Change of Control of VERTEX. Any trademark for a Drug Product will be selected by, and will be the property of, NOVARTIS.
Co-Labeling. In any country in which VERTEX has the right to co-promote Drug Product under this Agreement and Japan, to the extent not prohibited by law or regulation and subject to approval by the FDA or its equivalent, Drug Product (including labels, packaging and inserts) and all promotional materials for the same will bear both HMR's and VERTEX's company names and logos with equal prominence (including equal sized type face), or if equal prominence is prohibited by law, with such prominence as may otherwise be permitted by law. In countries (other than Japan) in which VERTEX is not co-promoting Drug Product under this Agreement, to the extent not prohibited by law or regulation and subject to approval by the FDA or its equivalent, Drug Product (including labels, packaging and inserts) and all promotional materials for the same, will include VERTEX's company name (in the English alphabet) and logo with the designation: "under license from."
(a) REVIEW OF REGULATORY FILINGS. HMR will permit VERTEX to review all material regulatory filings which relate to product labeling, and all proposed labels, packaging, package inserts, and promotional materials required under the Agreement to bear VERTEX's name, prior to the filing of any such materials with any regulatory authority.
Co-Labeling. All labels, packaging and package inserts, sales literature, and product advertising relative to Drug Products shall bear the names of both SCHERING and VERTEX in a prominent position or to the extent permitted by law in a particular jurisdiction. SCHERING will cooperate with any reasonable request of VERTEX directed toward facilitating approval by a regulatory authority for co-labeling consistent with this Section 5.6.
Co-Labeling. All Drug Products sold in the Territory shall bear reference to Taisho's and Vertex's logos and trademarks with equal prominence or to the extent not ** prohibited by local law. Vertex's name, where it shall appear, will be written in the English language.